nirsevimab

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Evaluate PK Profile

Conditions

Evaluate PK Profile

Trial Timeline

Jun 22, 2021 → Nov 18, 2021

NCT ID

NCT04840849

About nirsevimab

nirsevimab is a phase 1 stage product being developed by AstraZeneca for Evaluate PK Profile. The current trial status is completed. This product is registered under clinical trial identifier NCT04840849. Target conditions include Evaluate PK Profile.

What happened to similar drugs?

0 of 1 similar drugs in Evaluate PK Profile were approved

Approved (0) Terminated (0) Active (1)

🔄DenosumabAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06042049	Phase 3	Active	Jul 27, 2023	Aug 15, 2025	Respiratory Syncytial Virus Infections
NCT05437510	Phase 3	Completed	Aug 8, 2022	Apr 9, 2025	RSV Immunization
NCT04840849	Phase 1	Completed	Jun 22, 2021	Nov 18, 2021	Evaluate PK Profile
NCT04484935	Phase 2	Completed	Aug 19, 2020	Feb 17, 2023	RSV Infection

Competing Products

3 competing products in Evaluate PK Profile

See all competitors

Product	Company	Stage	Hype Score
Exenatide/Exenatide extended release + Dapagliflozin + Placebo	AstraZeneca	Pre-clinical	26
Denosumab	Amgen	Phase 3	40
Afamelanotide	Clinuvel Pharmaceuticals	Phase 1	23